



(51) International Patent Classification:
C07K 14/705 (2006.01)

(21) International Application Number:

PCT/US2018/022270

(22) International Filing Date:

13 March 2018 (13.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/472,554	16 March 2017 (16.03.2017)	US
62/472,558	16 March 2017 (16.03.2017)	US
62/472,569	16 March 2017 (16.03.2017)	US
62/472,572	16 March 2017 (16.03.2017)	US
62/472,573	17 March 2017 (17.03.2017)	US
62/475,204	22 March 2017 (22.03.2017)	US
62/537,939	27 July 2017 (27.07.2017)	US
62/574,165	18 October 2017 (18.10.2017)	US
62/582,266	06 November 2017 (06.11.2017)	US

(71) Applicant: **ALPINE IMMUNE SCIENCES, INC.**
[US/US]; 201 Elliott Avenue West, Suite 230, Seattle,
Washington 98119 (US).


(72) Inventors: **SWANSON, Ryan**; 201 Elliott Avenue West,
Suite 230, Seattle, Washington 98119 (US). **KORNACK-
ER, Michael**; 201 Elliott Avenue West, Suite 230, Seat-
tle, Washington 98119 (US). **MAURER, Mark F.**; 201 El-
liott Avenue West, Suite 230, Seattle, Washington 98119
(US). **ARDOUREL, Dan**; 201 Elliott Avenue West, Suite
230, Seattle, Washington 98119 (US). **DEMONTE, Daniel
William**; 201 Elliott Avenue West, Suite 230, Seattle,
Washington 98119 (US). **KUIJPER, Joseph L.**; 201 Elliott
Avenue West, Suite 230, Seattle, Washington 98119 (US).

(74) Agent: **AIKEN, Charity** et al.; 12531 High Bluff Drive,
Suite 100, San Diego, California 92130-2040 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

(54) Title: CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF

FIG. 3A



(57) Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

[Continued on next page]

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*